Key facts
- Mestag Therapeutics’s last known valuation is $54.3M (Oct 2024).
- It has raised $88.7M; the latest was Later Stage VC ($40.0M) in Mar 2026.
- Notable investors include Innovate UK, GV, Johnson & Johnson JJDC, SV Health Investors, Forbion — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mestag Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mestag Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mestag Therapeutics
Developer of a biotechnology research and development platform designed to offer therapeutics for the treatment of cancer and inflammatory diseases. The company's platform exploits emerging insights related to the role of activated fibroblast populations in disease for developing therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory diseases and cancer, enabling the medical industry to combat and cure rare and life-threatening diseases.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 43
- Website
- mestagtherapeutics.com/
- Ownership
- Privately Held (backing)
Mestag Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mestag Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mestag Therapeutics in its N-PORT filings yet. We sweep new filings monthly.